Login to Your Account



FDA OKs Sage bid in PPD, may speed time to market

By Randy Osborne
Staff Writer

Tuesday, December 6, 2016

CEO Jeff Jonas told BioWorld Today the regulatory path OK'd by the FDA for Sage Therapeutics Inc.'s drug SAGE-547 hurries the potential availability in a severe unmet need by at least a year, and "shows the strength of the data package" brought to gatekeepers who said yes to a plan that the company had in mind all along.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription